Is finerenone useful in hypertrophic cardiomyopathy (HCM)?

Finerenone is NOT useful in hypertrophic cardiomyopathy (HCM)

Finerenone has no established role in HCM management and is not mentioned in any HCM treatment guidelines. The drug label evidence provided 1 pertains to ropinirole (a dopamine agonist for Parkinson's disease), not finerenone, indicating a data retrieval error. The actual finerenone research 2, 3, 4 focuses on cardiovascular-kidney-metabolic syndrome, diabetic kidney disease, and heart failure with preserved ejection fraction (HFpEF)—but none of these studies specifically address HCM.

Why Finerenone Doesn't Fit HCM Pathophysiology

HCM is fundamentally a disease of sarcomeric hypercontractility caused by genetic mutations affecting cardiac myosin and related proteins 5. The primary pathophysiologic driver is excessive cross-bridge cycling leading to dynamic left ventricular outflow tract obstruction (LVOTO), diastolic dysfunction, and myocardial ischemia 6, 7, 8.

Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that targets inflammation, fibrosis, and oxidative stress 3, 4. While these processes occur in HCM 9, they are secondary consequences rather than primary therapeutic targets. The established HCM treatment paradigm focuses on:

• Reducing contractility (beta-blockers, verapamil, disopyramide)
• Directly inhibiting sarcomeric function (cardiac myosin inhibitors like mavacamten)
• Mechanical gradient reduction (septal reduction therapy)

None of these mechanisms align with finerenone's pharmacology.

What the Guidelines Actually Recommend

The 2024 AHA/ACC HCM guidelines 7, 8 and 2011 ACCF/AHA guidelines [6-6] establish a clear treatment hierarchy:

First-line therapy for symptomatic obstructive HCM:

• Beta-blockers (Class I, Level B): Titrate to resting heart rate <60-65 bpm 6, 10
• Verapamil (Class I, Level B): 240-480 mg/day if beta-blockers fail or are contraindicated, but use cautiously with high gradients (>100 mmHg), severe dyspnea, or hypotension 6, 10, 8

Second-line options:

• Disopyramide combined with beta-blockers or verapamil (Class IIa, Level B) 6
• Mavacamten (cardiac myosin inhibitor): For patients with persistent symptoms despite optimal medical therapy 7, 8, 5
• Septal reduction therapy: For severe drug-refractory symptoms with LVOT gradient ≥50 mmHg 6, 10, 6

Agents to AVOID in obstructive HCM (Class III: Harm):

• Pure vasodilators (ACE inhibitors, ARBs, dihydropyridine calcium channel blockers) 6
• High-dose diuretics 11, 10
• Positive inotropes 6, 10

The Finerenone Evidence Gap

While preclinical data show finerenone reduces cardiac hypertrophy in metabolic/hypertensive models 2, this represents a completely different disease mechanism than genetic HCM. The mouse model used combined high-fat diet, fructose, and L-NAME to induce hypertension-driven hypertrophy—a phenotype of secondary cardiac remodeling, not primary sarcomeric disease.

The clinical trials cited (FIDELIO-DKD, FIGARO-DKD, FINEARTS-HF) 3, 4 enrolled patients with:

• Diabetic kidney disease with albuminuria
• Heart failure with preserved/mildly reduced ejection fraction (general population)

None specifically studied HCM patients. HFpEF in the general population has distinct pathophysiology (metabolic dysfunction, inflammation, systemic hypertension) compared to HCM-related diastolic dysfunction (sarcomeric hypercontractility, LVOTO, myocardial disarray).

Common Pitfalls to Avoid

1. Don't confuse HCM with hypertensive heart disease: Finerenone may benefit hypertension-induced left ventricular hypertrophy 2, but HCM is a genetic sarcomeric disorder requiring different treatment
2. Don't extrapolate HFpEF data to HCM: The FINEARTS-HF trial 3, 4 excluded patients with obstructive HCM or severe valvular disease
3. Don't use ACE inhibitors/ARBs in obstructive HCM: These are potentially harmful 6, and finerenone shares similar vasodilatory properties that could worsen LVOTO

What to Do Instead

For symptomatic HCM patients:

1. Start beta-blockers (metoprolol, atenolol, propranolol) and titrate to heart rate <60-65 bpm 6, 10
2. If inadequate response, switch to verapamil (start low, titrate to 480 mg/day) 10, 8
3. If still symptomatic, add disopyramide or consider mavacamten 7, 8, 5
4. For severe drug-refractory obstruction, refer to comprehensive HCM center for septal reduction therapy 10, 6, 7

Treat comorbidities (hypertension, diabetes, hyperlipidemia) per standard guidelines 10, 6, but avoid agents that worsen LVOTO.